These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 36215989)

  • 1. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
    Martin T; Lin Y; Agha M; Cohen AD; Htut M; Stewart AK; Hari P; Berdeja JG; Usmani SZ; Yeh TM; Olyslager Y; Goldberg JD; Schecter JM; Madduri D; Jackson CC; Deraedt W; Gries KS; Fastenau JM; Trudeau JJ; Akram M; Pacaud L; Jakubowiak A; Jagannath S
    Lancet Haematol; 2022 Dec; 9(12):e897-e905. PubMed ID: 36215989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
    Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
    Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
    Martin T; Usmani SZ; Berdeja JG; Agha M; Cohen AD; Hari P; Avigan D; Deol A; Htut M; Lesokhin A; Munshi NC; O'Donnell E; Stewart AK; Schecter JM; Goldberg JD; Jackson CC; Yeh TM; Banerjee A; Allred A; Zudaire E; Deraedt W; Olyslager Y; Zhou C; Pacaud L; Madduri D; Jakubowiak A; Lin Y; Jagannath S
    J Clin Oncol; 2023 Feb; 41(6):1265-1274. PubMed ID: 35658469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjusted comparison of outcomes between patients from CARTITUDE-1
    Mateos MV; Weisel K; Martin T; Berdeja JG; Jakubowiak A; Stewart AK; Jagannath S; Lin Y; Diels J; Ghilotti F; Thilakarathne P; Perualila NJ; Cabrieto J; Haefliger B; Erler-Yates N; Hague C; Jackson CC; Schecter JM; Strulev V; Nesheiwat T; Pacaud L; Einsele H; Moreau P
    Haematologica; 2023 Aug; 108(8):2192-2204. PubMed ID: 36546453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
    Costa LJ; Lin Y; Cornell RF; Martin T; Chhabra S; Usmani SZ; Jagannath S; Callander NS; Berdeja JG; Kang Y; Vij R; Godby KN; Malek E; Neppalli A; Liedtke M; Fiala M; Tian H; Valluri S; Marino J; Jackson CC; Banerjee A; Kansagra A; Schecter JM; Kumar S; Hari P
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):326-335. PubMed ID: 34840088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
    Cohen AD; Hari P; Htut M; Berdeja JG; Usmani SZ; Madduri D; Olyslager Y; Goldberg JD; Schecter JM; Jackson CC; Gries KS; Fastenau JM; Valluri S; Deraedt W; Akram M; Crawford R; Morrison R; Doward L; Morgan K; Seldam ST; Jakubowiak A; Jagannath S
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):68-77. PubMed ID: 36357295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
    Ri M; Suzuki K; Ishida T; Kuroda J; Tsukamoto T; Teshima T; Goto H; Jackson CC; Sun H; Pacaud L; Fujikawa E; Yeh TM; Hatayama T; Aida K; Sunagawa Y; Iida S
    Cancer Sci; 2022 Dec; 113(12):4267-4276. PubMed ID: 36052883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
    Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
    Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
    San-Miguel J; Dhakal B; Yong K; Spencer A; Anguille S; Mateos MV; Fernández de Larrea C; Martínez-López J; Moreau P; Touzeau C; Leleu X; Avivi I; Cavo M; Ishida T; Kim SJ; Roeloffzen W; van de Donk NWCJ; Dytfeld D; Sidana S; Costa LJ; Oriol A; Popat R; Khan AM; Cohen YC; Ho PJ; Griffin J; Lendvai N; Lonardi C; Slaughter A; Schecter JM; Jackson CC; Connors K; Li K; Zudaire E; Chen D; Gilbert J; Yeh TM; Nagle S; Florendo E; Pacaud L; Patel N; Harrison SJ; Einsele H
    N Engl J Med; 2023 Jul; 389(4):335-347. PubMed ID: 37272512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
    Mi JQ; Zhao W; Jing H; Fu W; Hu J; Chen L; Zhang Y; Yao D; Chen D; Schecter JM; Yang F; Tian X; Sun H; Zhuang SH; Ren J; Fan X; Jin J; Niu T; Chen SJ
    J Clin Oncol; 2023 Feb; 41(6):1275-1284. PubMed ID: 36269898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.
    Martin T; Krishnan A; Yong K; Weisel K; Mehra M; Nair S; Qi K; Londhe A; Diels J; Crivera C; Jackson CC; Olyslager Y; Vogel M; Schecter JM; Banerjee A; Valluri S; Usmani SZ; Berdeja JG; Jagannath S
    EJHaem; 2022 Feb; 3(1):97-108. PubMed ID: 35846215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
    Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
    Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.
    Hansen DK; Lu X; Puglianini OC; Sorensen S; Usmani SZ; Zhang E; Huo S; Zhang Y; Qureshi ZP; Jagannath S
    Front Immunol; 2024; 15():1408892. PubMed ID: 39234256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
    Jagannath S; Jackson CC; Schecter JM; Lendvai N; Sun H; Akram M; Patel N; Martin TG
    Expert Opin Biol Ther; 2024 May; 24(5):339-350. PubMed ID: 38738379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
    Htut M; Dhakal B; Cohen AD; Martin T; Berdeja JG; Usmani SZ; Agha M; Jackson CC; Madduri D; Deraedt W; Zudaire E; Yeh TM; Xu X; Pacaud L; Akram M; Jagannath S
    Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):882-888. PubMed ID: 37716872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
    Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
    Front Immunol; 2022; 13():991092. PubMed ID: 36119032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
    San-Miguel J; Dhakal B; Patel N; Schecter JM; Lendvai N; Einsele H
    Future Oncol; 2024; 20(33):2509-2520. PubMed ID: 39110421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
    Weisel K; Krishnan A; Schecter JM; Vogel M; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Yalniz F; Nesheiwat T; Van Sanden S; Diels J; Valluri S; Usmani SZ; Berdeja JG; Jagannath S; Martin T
    Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):690-701. PubMed ID: 35764490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
    Martin TG; Madduri D; Pacaud L; Usmani SZ
    Future Oncol; 2023 Nov; 19(34):2297-2311. PubMed ID: 37497629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
    Weisel K; Martin T; Krishnan A; Jagannath S; Londhe A; Nair S; Diels J; Vogel M; Schecter JM; Banerjee A; Berdeja JG; Nesheiwat T; Garrett A; Qi K; Valluri S; Usmani SZ; Yong K
    Clin Drug Investig; 2022 Jan; 42(1):29-41. PubMed ID: 34822128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.